Form 8-K · Current report
Zimmer Biomet 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001136869
- Accession no.
- 0001193125-26-333761
Summary
Zimmer Biomet reported second-quarter 2026 net sales of $2.177 billion, up 4.8% year over year, with diluted earnings per share of $1.03 and adjusted diluted earnings per share of $2.07, and raised its full-year 2026 revenue and adjusted EPS guidance. CEO Ivan Tornos attributed the results to top- and bottom-line performance, go-to-market changes and momentum from the company's innovation cycle.
Key points
- Second-quarter net sales rose 4.7% on a constant-currency basis and 4.0% on an organic constant-currency basis, which excludes the April 2025 Paragon 28 acquisition.
- Diluted earnings per share of $1.03 rose 33.8%, while adjusted diluted earnings per share of $2.07 was consistent with the prior-year period.
- Full-year 2026 guidance was raised to reported revenue growth of 3.9%-4.9% and adjusted diluted EPS of $8.47-$8.59.
- Zimmer Biomet received FDA 510(k) clearance and completed first cases of its next-generation ROSA Shoulder System, and named Chintan Desai president of its Asia Pacific Region to replace Sang Yi, who departs on Aug. 28.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 5, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.